Literature DB >> 17602781

The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study.

William Bernal1, Yun Ma, Heather M Smith, Bernard Portmann, Julia Wendon, Diego Vergani.   

Abstract

BACKGROUND/AIMS: The cause of cryptogenic ('seronegative') acute liver failure (ALF) is unknown; the presence of non-organ specific autoantibodies (NOSA) may indicate an autoimmune pathogenesis. We investigated the prevalence of autoimmune features including antibodies to soluble liver antigen (anti-SLA) determined by Radioligand assay (RLA) in ALF patients.
METHODS: The prevalence and relationship to the immunoglobulin (Ig) response of NOSA and anti-SLA were determined in 73 ALF patients of different causes. Patients were scored using the revised system for diagnosis of autoimmune hepatitis (AIH).
RESULTS: Autoantibodies were present in 23 (32%) patients; 16 had anti-SLA, 6 ANA, 4 ASM and 1 AMA. They were absent in paracetamol-related disease and present in 23 of 53 (43%) of non-paracetamol (NP) cases (p<0.0003). Two of 16 (13%) with NP drug-induced (NPDI), 9 of 21 (43%) viral and 5 of 16 (31%) cryptogenic cases had anti-SLA. NOSA and anti-SLA were not associated with liver injury severity or outcome. IgM was higher in those with viral disease (p<0.00001). AIH scores classified 50% of cryptogenic cases as 'probable autoimmune hepatitis'.
CONCLUSIONS: Autoantibodies are common in ALF; cryptogenic cases have features suggestive of an autoimmune pathogenesis. IgM is elevated in viral cases but infrequently in ALF of other causes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602781     DOI: 10.1016/j.jhep.2007.05.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  23 in total

1.  Clinicopathological features of severe and fulminant forms of autoimmune hepatitis.

Authors:  Shin Yasui; Keiichi Fujiwara; Yutaka Yonemitsu; Shigeto Oda; Masayuki Nakano; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2010-09-07       Impact factor: 7.527

2.  Autoimmune acute liver failure: proposed clinical and histological criteria.

Authors:  R Todd Stravitz; Jay H Lefkowitch; Robert J Fontana; M Eric Gershwin; Patrick S C Leung; Richard K Sterling; Michael P Manns; Gary L Norman; William M Lee
Journal:  Hepatology       Date:  2011-01-05       Impact factor: 17.425

3.  [Autoimmune liver diseases].

Authors:  N Pannicke; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 4.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

5.  Two cases of food additive-induced severe liver damage associated with positive results on lymphocyte stimulation test and for antinuclear antibodies.

Authors:  Rena Kaneko; Chitose Ohishi; Miniru Kim; Masaaki Shiina; Satoshi Kusayanagi; Masazumi Ogawa; Kazuo Munakata; Kyoichi Mizuno; Yuzuru Sato
Journal:  Clin J Gastroenterol       Date:  2012-06-04

Review 6.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

7.  Prevalence and Significance of Autoantibodies in Children With Acute Liver Failure.

Authors:  Michael R Narkewicz; Simon Horslen; Steven H Belle; David A Rudnick; Vicky L Ng; Philip Rosenthal; Rene Romero; Kathleen M Loomes; Song Zhang; Regina M Hardison; Robert H Squires
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 8.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 9.  Mechanisms of immune-mediated liver injury.

Authors:  David H Adams; Cynthia Ju; Shashi K Ramaiah; Jack Uetrecht; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

Review 10.  Toward unraveling the complexity of simple epithelial keratins in human disease.

Authors:  M Bishr Omary; Nam-On Ku; Pavel Strnad; Shinichiro Hanada
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.